Demand for Molecular Diagnostics to Propel Enteric Disease Testing Market to USD 4.2 Billion by 2020

The global enteric disease testing market is estimated to reach USD 4.2 Billion in 2020, growing at a CAGR of 5.6% from 2016 to 2020, according to a new market research report Enteric Disease Testing Market – Global Bacterial, Viral and Parasitic Diseases Analysis and Forecast 2013-2020, published by iHealthcareAnalyst, Inc.

Visit the Enteric Disease Testing Market – Global Bacterial, Viral and Parasitic Diseases Analysis and Forecast 2013-2020 report at http://www.ihealthcareanalyst.com/report/enteric-disease-testing-market/

The diagnosis of acute gastroenteritis (AGE) caused by enteric pathogens, such as Salmonella spp., Shiga toxin–producing Escherichia coli (STEC), and Campylobacter spp., has traditionally been based on culture methods from patients with culture-confirmed infections. Enteric infections enter the body through the mouth and intestinal tract and are usually spread through contaminated food and water or by contact with infected person. The enteric disease testing market report estimates the market size (Revenue USD million - 2013 to 2020) for market segmentation based on casual organism for enteric disease type (bacterial agents - C. difficile, Campylobacteriosis, Cholera, E. coli, H. pylori, Salmonellosis, Shigellosis; viral agents – Norovirus, Rotavirus; and parasitic agents – Amebiasis, Cryptosporidiosis, Giardiasis), and forecasts growth trends (CAGR% - 2016 to 2020). It also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent acquisitions and alliances.

The global enteric disease testing market is segmented as:

1. Indication (Enteric Disease)
1.1. Bacterial Agents
1.1.1. C. difficile Infection
1.1.2. Campylobacteriosis
1.1.3. Cholera
1.1.4. E. coli Infection
1.1.5. H. pylori Infection
1.1.6. Salmonellosis
1.1.7. Shigellosis
1.2. Viral Agents
1.2.1. Norovirus Infection
1.2.2. Rotavirus Infection
1.3. Parasitic Agents
1.3.1. Amebiasis
1.3.2. Cryptosporidiosis
1.3.3. Giardiasis

2. Geography (Region, Country)
2.1. North America (U.S., Canada)
2.2. Latin America (Brazil, Mexico, Rest of LA)
2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4. Asia Pacific (Japan, China, India, Rest of APAC)
2.5. Rest of the World

3. Company Profiles
3.1. Alere, Inc.
3.2. Becton, Dickinson & Company
3.3. Biomerica, Inc.
3.4. bioMérieux SA
3.5. Bio-Rad
3.6. Cepheid, Inc.
3.7. Coris Bioconcept
3.8. Diasorin
3.9. Meridian Bioscience, Inc.
3.10. Quest Diagnostics
3.11. Trinity Biotech

iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.

Ana Aitawa
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Phone: (314) 736-9294.
Email: sales@ihealthcareanalyst.com
http://www.ihealthcareanalyst.com

This release was published on openPR.